Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction

Circulation

Volumn 94, Issue 4, 1996, Pages 690-697

  Benedict, Claude R ^a   Shelton, Brent ^b   Johnstone, David E ^c   Francis, Gary ^d   Greenberg, Barry ^e   Konstam, Marvin ^f   Probstfield, Jeffrey L ^g   Yusuf, Salim ^h  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^d UNIVERSITY OF MINNESOTA   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f TUFTS MEDICAL CENTER   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^h MCMASTER UNIVERSITY   (Canada)

Author keywords

atrial natriuretic factor; heart failure; norepinephrine

Indexed keywords

ATRIAL NATRIURETIC FACTOR; ENALAPRIL; NEUROHORMONE; NORADRENALIN; PLACEBO; RENIN;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NORADRENALIN BLOOD LEVEL; PLASMA RENIN ACTIVITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; UNSTABLE ANGINA PECTORIS;

EID: 0029758535     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.4.690     Document Type: Article

References (30)

1. Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol. 1978;41:233-243.
2. Levine TB, Francis GS, Goldsmith SR, Simon A, Cohn JN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities. Am J Cardiol. 1982;49:1659-1666.
3. Cody RJ, Atlas SA, Laragh JH, Kubo SH, Covit AB, Ryman KS, Shaknovich A, Pondolfino K, Clark M, Camargo MJF, Scarborough RM, Lewicki JA. Atrial natriuretic factor in normal subjects and heart failure patients: plasma levels and renal hormonal and hemodynamic responses to peptide infusion. J Clin Invest. 1986;78:1362-1374.
4. Curtiss C, Cohn JN, Vrobel T, Franciosa JA. Role of renin-angiotensin system in systemic vasoconstriction of chronic congestive heart failure. Circulation. 1978;58:763-770.
5. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
6. Sigurdsson A, Amtorp O, Gundersen T, Nilsson B, Jouko R, Swedberg K, for the Ramipril Trial Study Group. Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effect of ramipril. Br Heart J. 1994;72:422-427.
7. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation. 1986;73:257-262.
8. Gottlieb SS, Kukin ML, Ahern D, Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol. 1989;13:1534-1539.
9. Francis GS, Benedict CR, Johnstone DE, Kirlin P, Nicklas J, Liang, CS, Kubo SH, Rudin-Toretsky E, Yusuf S, for SOLVD Investigators. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation. 1990;82:1724-1729.
10. The SOLVD Investigators. Studies of left ventricular dysfunction (SOLVD): rationale, design and methods - two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. Am J Cardiol. 1990;66:315-322.
11. Benedict CR, Johnstone DE, Weiner DH, Bourassa MG, Bittner V, Kay R, Kirlin P, Greenberg B, Kohn RM, Nicklas JM, McIntyre K, Quinones MA, Yusuf S, for the SOLVD Investigators. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the registry of studies of left ventricular dysfunction. J Am Coll Cardiol. 1994;23:1410-1420.
12. Hussain MN, Benedict CR. Radioenzymatic microassay for simultaneous estimations of dopamine, norepinephrine and epinephrine in plasma, urine and tissues. Clin Chem. 1985;31:1861-1864.
13. Sealey J, Laragh JH. How to do a plasma renin assay. In: Laragh JG, ed. Topics in Hypertension. New York, NY: York Medical Books; 1980:244-256.
14. Bodola F, Benedict CR. Rapid simplified radioimmunoassay of arginine vasopressin and atrial natriuretic peptide in plasma. Clin Chem, 1988;34:970-973.
15. Fleiss JL, Bigger JT Jr, McDermott M. Nonfatal myocardial infarction is, by itself, an inappropriate end point in clinical trials in cardiology. Circulation. 1990;81:684-685.
16. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med. 1992; 327:685-691.
17. Cohn J, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector TS. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
18. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 1990;82:1730-1736.
19. Kirlin, PC, Benedict CR, Shelton BJ, Francis G, Nicklas J, Liang CS, Kubo S, Johnstone D, Probstfield J, Yusuf S, for the SOLVD Investigators. Neurohumoral variability in left ventricular dysfunction. Am J Cardiol. 1995;75:354-359.
20. Benedict CR, Francis G, Shelton BJ, Johnstone D, Kubo S, Kirlin PC, Nicklas J, Liang C-S, Konstam MA, Greenberg B, Yusuf S, for the SOLVD Investigators. Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. Am J Cardiol. 1995;75:1151-1157.
21. Leimbach WN, Wallin G, Victor RG, Aylward PE, Sundlof G, Mark AL. Direct evidence from intraneuronal recordings for increased central sympathetic outflow in patients with heart failure. Circulation. 1986;73:913-919.
22. Cohn JN. Mechanisms in heart failure and the role of angiotensin-converting enzyme inhibition. Am J Cardiol. 1990; 66:2D-6D.
23. Francis GS, McDonald KM, Cohn JN. Neurohumoral activation in preclinical heart failure: remolding and the potential for intervention. Circulation. 1993;87(suppl IV):IV-90-IV-96.
24. Benedict CR. Neurohumoral aspects of heart failure. Cardiol Clin North Am. 1994;12:9-23.
25. Waagstein F, Bristow MR, Swedberg K, Caprerini F, Folwer MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A, for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342:1441-1446.
26. CIBIS Investigators. A randomization trial of β-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90:1765-1773.
27. Rodeheffer RJ, Tanaka I, Imada T, Hollister AS, Robertson D, Inagami T. Atrial pressure and secretion of atrial natriuretic factor into the human central circulation. J Am Coll Cardiol. 1986;8:18-26.
28. Bates ER, Shenker Y, Grekin RJ. The relationship between plasma levels of immunoreactive atrial natriuretic hormone and hemodynamic function in man. Circulation. 1986;73:1155-1161.
29. Lerman A, Gibbons RJ, Rodeheffer RJ, Bailey KR, McKinley LJ, Heublein DM, Burnett JC Jr. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left ventricular dysfunction. Lancet. 1993;341:1105-1109.
30. Rouleau JL, Packer M, Moye L, De Champlain J, Bichet D, Klein M, Rouleau JR, Sussex B, Arnold JM, Sestier F, Parker JO, McEwan P, Bernstein V, Cuddy TE, Lamas G, Gottlieb SS, McCans J, Nadeau C, Delage F, Wun CC, Pfeffer MA. Prognostic value of neurohormonal activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol. 1994;24:583-591.